InflaRx N.V., a clinical-stage biopharmaceutical company specializing in C5a technology, is making waves in Germany and the United States with its unique inhibitors. C5a, an inflammatory mediator involved in the progression of a variety of autoimmune and inflammatory diseases, is the focus of the company's research. In particular, InflaRx N.V.'s lead product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that has completed Phase III clinical trials for the treatment of hidradenitis suppurativa, pyoderma gangraenosum, anti-neutrophil cytoplasm antibody associated vasculitis, and PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma. In addition to vilobelimab, the company is developing oral small molecule drug candidate INF904 and IFX002, a pre-clinical development-stage treatment for chronic inflammation and autoimmune diseases. InflaRx N.V. has also entered co-development and clinical trial collaboration and supply agreements with Beijing Defengrei Biotechnology Co. Ltd. and Merck & Co. Inc., respectively. The company, formerly known as Fireman B.V., was founded in 2007 and is based in Jena, Germany.